Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to release the body’s own growth hormone (GH). Increased GH secretion subsequently raises circulating insulin-like growth factor-1 (IGF-1) levels, promoting lipolysis (fat breakdown), particularly within visceral adipose tissue surrounding the abdominal organs. Unlike recombinant human growth hormone, tesamorelin stimulates endogenous GH production while maintaining the body’s normal hormonal feedback mechanisms.
Tesamorelin selectively binds to growth hormone-releasing hormone receptors on pituitary somatotroph cells, stimulating pulsatile secretion of endogenous growth hormone.
This physiologic increase in GH results in:
Unlike direct growth hormone therapy, tesamorelin relies on the body’s own endocrine system to regulate hormone production, reducing the risk of continuous supraphysiologic GH exposure.
The GH/IGF-1 axis governs two primary biological functions: Somatic Growth and Metabolism.
Growth (Somatic & Linear)
Metabolism
Published clinical research has demonstrated that tesamorelin may provide the following benefits in appropriately selected patients:
It is important to note that tesamorelin is not a general weight-loss medication. Clinical trials have demonstrated reductions primarily in visceral fat, with relatively little effect on subcutaneous fat or overall body weight.
Like all prescription medications, tesamorelin may cause adverse effects. Although rare, the most commonly reported side effects include:
Most adverse events reported during clinical trials were mild to moderate in severity. Patients receiving tesamorelin should be monitored for changes in glucose metabolism and IGF-1 concentrations.
Tesamorelin should not be used in patients with:
Patients with diabetes or prediabetes should be monitored carefully, as tesamorelin may affect glucose metabolism.
Tesamorelin is FDA-approved for: Reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
Tesamorelin is not FDA-approved for:
Although physicians may prescribe FDA-approved medications for off-label indications when clinically appropriate, these uses have not been approved by the FDA.
Human Studies
Tesamorelin has been extensively studied in randomized, placebo-controlled clinical trials involving adults with HIV-associated lipodystrophy.
Published studies have demonstrated:
Long-term extension studies demonstrated that reductions in visceral fat are generally maintained during continued therapy but tend to diminish after treatment is discontinued.
Animal & Preclinical Research
Preclinical studies demonstrated that tesamorelin:
These investigations formed the basis for subsequent human clinical trials and FDA approval.
Randomized Clinical Trials
Falutz J, et al. Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation
https://pubmed.ncbi.nlm.nih.gov/20101189/
Falutz J, et al. Effects of Tesamorelin (TH9507) in Human Immunodeficiency Virus-Infected Patients With Excess Abdominal Fat: Pooled Analysis of Two Multicenter, Double-Blind, Placebo-Controlled Phase III Trials
https://pubmed.ncbi.nlm.nih.gov/20554713/
Stanley TL, et al. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation
https://pubmed.ncbi.nlm.nih.gov/25038357/
Stanley TL, et al. Reduction in Visceral Adiposity Is Associated With Improved Metabolic Profile in HIV-Infected Patients Receiving Tesamorelin
https://pubmed.ncbi.nlm.nih.gov/22495074/
Review Articles
Spooner LM, Olin JL. Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy
https://pubmed.ncbi.nlm.nih.gov/22298602/
Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin
https://pubmed.ncbi.nlm.nih.gov/21283099/
LiverTox®: Tesamorelin
https://www.ncbi.nlm.nih.gov/books/NBK548730/
Clinical Review Report: Tesamorelin (EGRIFTA®)
https://www.ncbi.nlm.nih.gov/books/NBK539127/
Recent Research
Russo SC, et al. Efficacy and Safety of Tesamorelin in People with HIV Receiving Integrase Inhibitors
https://pubmed.ncbi.nlm.nih.gov/38905488/
Badran AS, et al. A Meta-analysis of Randomized Controlled Trials Evaluating Tesamorelin
The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice.
This content was generated with the assistance of artificial intelligence (AI) and reviewed for general accuracy; however, it may contain errors or omissions and should not replace professional medical judgment. Individuals should consult a qualified healthcare provider before beginning or changing any medical treatment.
Tesamorelin is FDA-approved only for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Any other use is considered off-label. Individual results vary, and no specific outcome or benefit can be guaranteed.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.
# Ipamorelin